Floatz logo

Edoxaban

Cerebral Infarction

Xijing HospitalSmall moleculePhase 2/3Dormant
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

21 Active assets in the Cerebral Infarction cohort.

Asset / SponsorPhaseRating
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Asan Medical Center
Phase 4BBB
Acetylsalicylic Acid
Sclnow Biotechnology Co., Ltd.
Phase 4BBB
Sovateltide
Pharmazz, Inc.
Phase 4BBB
Plavix
The Second Hospital of Anhui Medical University
Phase 4BBB
Human Urinary Kallidinogenase
Huisheng Chen
Phase 4BB

View all 50 →

Same molecule, other indications

Edoxaban is also rated in:

atrial fibrillationDormant
A
Indicative ·
83 / 100
View asset →
intracerebral hemorrhageDormant
BBB
Indicative ·
78 / 100
View asset →
EmbolismDormant
BBB
Indicative ·
75 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →